Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Focus is key Barnie. I didn't have to read Iggy's posts yesterday or see the Level 2 data with my own eyes to know yesterday's reaction was a Short Attack on vulnerable worn out Longs.
Iggy,
What is vague about this ?
"As part of its portfolio refinement, the company has determined it will not pursue further clinical study of ADXS-HER2 at this time, but remains open to ISTs or licensing opportunities."
That seems pretty clear, no?
Just added 5,000 shares at 5.58 and lower.
FBG, Feels like you want a $20 price to just get out already. If a Big Deal is announced and the stock moves up to $20 will you sell your entire position? Are you still 100% in warrants?
Your optimism is contagious Iggy. Thanks for all you do here. I've had about one twentieth of my attention on Advaxis for about two years now. It used to be about 90%...hahaha.
I sold a different stock yesterday (txmd). I may add today.
https://finance.yahoo.com/news/therapeuticsmd-announces-publication-manuscript-women-203000365.html
Safety study has been published. Expect a bump coming but how big or how sustained is the big question. FDA may take a short while to respond...Shorts may respond (and cover) sooner.
I laughed
Seems like we have always been in wait and see mode with Advaxis FBG. Good to see some semblance of Corporate Governance manifest in the CEO change. Dan was running the company as if he had Carte Blanche for a ten year strategy in a family owned business. Time to make some deals.
Helpful...thanks Oakrock.
Greetings all,
I have been preoccupied since third week of April (don't ask)...been that long since I have paid attention to the day-to-day developments here. When O'Connor got the bullett I saw the PR in an email the morning it broke...haven't seen much since then.
Where are we at here? Catch me up. Just a few Bullet points will do just fine and will remind me of DOC getting a bullett, which will make me smile. Any key catalysts coming up?
We ever going to make money in this stock?
Kim, "Monday" and "Tuesday" are just concepts. All we have is the present moment. ;)
I scratched my head too Kim. Maybe they are talking about prospects for approval separate from box label?
LOL...I hope that was sarcasm. The stock is up 35% in two weeks. The Shorts are seeing nothing but losses. Of course, now they have to Buy to close their position. You think all 60 million will try to Buy at once?
I've always wondered if criminals would criminally short such a highly visible equity. This stock shows up on every list as one of the Top 3 shorted stocks on NYSE based on shares (# 2), days to cover (# 3) and percent of float (# 2). Criminals don't usually act in the light of day.
It was opined by another poster that some of the Institutions holding the stock have done some shorting to play short term trends. If so, they own the shares to cover their "paper" short. There could be many reasons why an institution holding a significant equity stake would NOT want to show that it is reducing its Long position and would rather reduce their Net Long shares "anonymously" by shorting.
Another likely issue is your calculation of the stock's float is different than WSJ (assume you are looking at their on-line shorting metrics) calculation. That could be a math issue (what is included, what is not included in the calculation) and also could be driven by using a dramatically different calculation for Insider and Institutional Holdings. (For example, Perhaps insiders have Options and you are counting them as Shares, vested vs non-vested, etc.)
That's a site for Nasdaq stocks. TXMD trades on NYSE.
Great trading today, if you're a Long. Also, no concern at all about having a "GAP" to fill. The stock opened $0.67 higher than previous close but already retraced and gap-filled on a retreat to $7.61 before moving and basing higher. Stock can surely fly from here.
The measured short data shows TXMD to be the second most shorted NYSE equity based on number of shares Short at 62.8MM as of data Friday, March 24th. WSJ-Online is my source. They show 40.6% of the float shorted. They call that 29 days to cover based on avg daily volume of 2.2MM shares per day.
Number 1 based on number of shares (62.8MM shares)
Number 3 based on number of days to cover at 29
Number 2 based percent of float at 40.6%
Gosh, you are so much smarter than these institutions who see value...
Institution / Shares Held / Percent Outstanding
Fidelity Management and Research Company 29,016,231 14.75
T. Rowe Price Associates, Inc. 23,663,196 12.03
Franklin Advisers Inc 11,196,777 5.69
Bank Of New York CO Inc. 8,328,893 4.24
Vanguard Group Inc 9,285,878 4.72
J.P. Morgan Investment Management Inc 6,306,983 3.21
Boston Co Asset Management LLC 5,119,207 2.60
J P Morgan Asset Management (UK) Ltd 5,970,061 3.04
BlackRock Fund Advisors 5,825,006 2.96
Wellington Management Company LLP 5,786,428 2.94
Dreyfus Corporation 4,788,701 2.43
State Street Corp 3,650,254 1.86
Gilder Gagnon Howe & CO LLC 3,411,162 1.73
Great Point Partners LLC 3,276,010 1.67
Millennium Management LLC 2,596,085 1.32
No...that's why Shorts like you are here. Longs are properly looking at the Future Value of the pipeline.
Nice. Thanks James.
It's the pipeline that could draw interest. The "data" is the trial results.
Here is the link for live webcast starts today at 1:00pmET.
http://ir.therapeuticsmd.com/phoenix.zhtml?c=60779&p=irol-EventDetails&EventId=5251425
FBG, Really seems like you have forgotten you invested in a clinical stage biotech company. Also, all of us long timers screwed up and invested way too early. We almost lost everything and would have lost everything if the R/S and recapitalization plan had failed. You were against that plan. It took other shareholders voting for it to save your very investment. (These memories are difficult for all of us.) Any of us could have gotten out in May '15 with a massive gain.
Here we are; start the new clock on the day of the R/S and count off time to fruition for a clinical stage biotech with the patience of Job and Hold for the reward. Sell and invest elsewhere if your timeline is different. Not sure what else there is to say.
I agree Gogo. The institutional ownership percentage is extremely impressive. Also large, of course, is the Short Position...about 62 million shares. It's been a staring contest here for a while between the two. That could change now. Shorting appeared to kick back up yesterday afternoon and the volume has dried up this morning. Appears Shorts didn't want a sp north of $7 and up-momentum headed into tomorrow's conference. Good luck Longs.
Stock is trading like it is being slowly and methodically accumulated...it might be a Short trying to close their position without creating a stir. Financing from a strategic partner would be the right way to send this one on a wild ride for Longs.
Amgen deal included a $40MM up front payment on pre-clinical science. It will take a $150-200MM up-front on Phase 3 science.
Post of the day MP. Thanks.
Short position is too big and way too stubborn. The ONLY thing that will break their backs is a Large BP Deal with significant ($150-200MM) upfront cash and/or FDA approval. As Longs, as the investment hypothesis gets stronger and stronger with trial progression and commercial development, you have two choices
1. Trust your ability to find value where the market has not and Hold and/or Increase your position
2. Sell and invest in a different stock NOT involved in a Long/Short tug o' war.
FBG/William Jay,
I have October 17, 2018 as warrant expiration date. At some point I know I researched/verified the date but please confirm on your side.
Ah, my bad. The plot thickens. No wonder y'all are so giddy.
James, There is no way they send Sara to do a presentation where "NEW" and important science is being presented. Not sure how they got around the "late breaking" criteria.
Any information from Cowen conference?
HD, One of the few cases where misery doesn't love company.
New Video posted on ADXS FB page on A n a l Cancer.
Enjoy the lovely day fellow Advaxins.
No I meant ADXS has been more of a target simply because of its Capital history. How many companies go through what Advaxis went through and then become a success? Very few. So, Advaxis has also been a target simply because of its history.
Iggy,
You have to throw in the company's history too; specifically the reverse split and recapitalization of the company a couple of years ago. Shorts got their opportunity, jumped on it, and here we are...or better yet, here they are.
Jefferies report out BUY with a $18 target.
Oppenheimer OUTPERFORM and increased target to $15.